Proportion of children who had sedation failure or inadequate level of sedation · children undergoing neurodiagnostic procedures
It is very uncertain whether chloral hydrate oral (60 mg/kg) changes proportion of children who had sedation failure or inadequate level… compared with music therapy (very low certainty).
1 finding from 1 review
Sedation duration (minutes) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · hormone‐sensitive prostate cancer
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
1 finding from 1 review
Quality of life · hormone‐sensitive prostate cancer
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · hormone‐sensitive prostate cancer
It is very uncertain whether degarelix changes cardiovascular events compared with standard androgen suppression therapy (very low certainty).
1 finding from 1 review
Injection site pain · hormone‐sensitive prostate cancer
Degarelix probably leads to higher injection site pain compared with standard androgen suppression therapy (moderate certainty).
1 finding from 1 review
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Foam showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Foam may leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Laser probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Laser showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review